mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer-Reference-Cited by-同舟云学术

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

Published:2013-07-31 Issue:196 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Elkabets Moshe¹²,Vora Sadhna²,Juric Dejan²,Morse Natasha¹,Mino-Kenudson Mari³,Muranen Taru⁴,Tao Jessica²,Campos Ana Bosch¹,Rodon Jordi⁵,Ibrahim Yasir H.⁵,Serra Violeta⁵,Rodrik-Outmezguine Vanessa⁶,Hazra Saswati⁷,Singh Sharat⁷,Kim Phillip⁷,Quadt Cornelia⁸,Liu Manway⁹,Huang Alan⁹,Rosen Neal⁶,Engelman Jeffrey A.²,Scaltriti Maurizio¹,Baselga José¹

Affiliation:

1. Human Oncology & Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.

2. Massachusetts General Hospital Cancer Center, CNY 149, 13th Street, Charlestown, MA 02129, USA.

3. Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

4. Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.

5. Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Pg Vall d’Hebron, 119-129, Barcelona 08035, Spain.

6. Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

7. Prometheus Therapeutics & Diagnostics, 9410 Carroll Park Drive, San Diego, CA 92121, USA.

8. Novartis Pharma AG, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland.

9. Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Abstract

Persistent mTORC1 signaling correlates with resistance to PI3K p110α inhibition in breast cancer, which can be overcome by inhibiting mTORC1.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

1. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

2. The Phosphoinositide 3-Kinase Pathway

3. Targeting PI3K signalling in cancer: opportunities, challenges and limitations

4. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

5. Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in Mice

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Rational Design of a Novel 6H-Benzo[c]chromen Series as Selective PI3Kα Inhibitors;Journal of Medicinal Chemistry;2024-08-19

3. PIK3CA mutations enhance the adipogenesis of ADSCs in facial infiltrating lipomatosis through TRPV1;iScience;2024-08

4. Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer;Nature Communications;2024-07-19

5. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06